LP-IR (NMR Insulin Resistance): Drugs That Distort This Test and What Your Score Really Means

What the LP-IR Score Actually Measures

The LP-IR (Lipoprotein Insulin Resistance) score is a validated composite derived from a single NMR LipoProfile panel. It does not require an oral glucose tolerance test or a fasting insulin draw. Instead, it uses six NMR-measured lipoprotein features: the sizes and concentrations of VLDL, LDL, and HDL particles, weighted and combined into a single number from 0 to 100.

The score was developed and validated in the MESA cohort (Multi-Ethnic Study of Atherosclerosis), where it predicted incident diabetes and cardiovascular events better than fasting glucose alone. A score of 45 or above corresponds to clinically meaningful insulin resistance, and scores in the 60-to-80 range are associated with a substantially elevated risk of progressing to type 2 diabetes within 5 to 10 years.

Why Six Lipoprotein Features Instead of One Number

Standard lipid panels give you total cholesterol, LDL-C, HDL-C, and triglycerides. None of those four numbers directly captures insulin resistance physiology. When insulin signaling is impaired, the liver overproduces large VLDL particles, HDL particles shrink, and LDL particles shift to a smaller, denser pattern. The LP-IR algorithm captures all of that simultaneously, which is why Shalaurova et al. (2014) found it outperformed any single lipid marker for detecting insulin resistance confirmed by hyperinsulinemic-euglycemic clamp, the gold-standard method.

Normal LP-IR Range

On the 0-to-100 scale:

| Score | Interpretation | |---|---| | 0 to 44 | No significant insulin resistance detected | | 45 to 60 | Moderate insulin resistance; lifestyle intervention warranted | | 61 to 100 | Marked insulin resistance; pharmacologic evaluation appropriate |

These thresholds come from the LabCorp NMR LipoProfile reference ranges, cross-referenced against the MESA validation data. Some integrative medicine clinicians use a more aggressive cutoff of 40, but the published validation study uses 45 as the primary threshold.

How Hormones and Life Stage Change Your LP-IR Score

This section matters for women specifically. LP-IR is not a static number. It shifts across the menstrual cycle, during pregnancy, and with menopause in ways that have nothing to do with true metabolic disease.

Reproductive Years and the Menstrual Cycle

Insulin sensitivity fluctuates across the cycle. The luteal phase is associated with mild physiologic insulin resistance driven by progesterone, which can nudge LP-IR upward by a few points compared with the follicular phase. If you are tracking LP-IR over time, try to draw blood in the early follicular phase (days 2 to 5 after the start of your period) for the most consistent comparison. No large trial has specifically quantified LP-IR variation across the menstrual cycle, so this recommendation is extrapolated from luteal-phase insulin resistance data reviewed in Yeung et al. (2010).

PCOS

Women with polycystic ovary syndrome carry a disproportionate insulin resistance burden. The AACE/ACE PCOS guidelines recognize insulin resistance as present in 65 to 80 percent of women with PCOS, regardless of weight. LP-IR captures this effectively because it reflects the dyslipidemia pattern driven by hyperinsulinemia, including small dense LDL, low HDL2, and large VLDL, that standard lipid panels often miss in normal-weight women with PCOS.

Perimenopause and Menopause

Estrogen loss is metabolically costly. The menopause transition is accompanied by a shift toward greater visceral adiposity, increased hepatic fat, and worsening insulin sensitivity even in women who do not gain weight. The Study of Women's Health Across the Nation (SWAN) documented rising fasting insulin and worsening lipid particle patterns during perimenopause. LP-IR scores tend to rise during this window, which means a score that was 38 in your early 40s may climb to 50 by your mid-50s without any change in diet or exercise. This is physiologically expected but clinically actionable.

Pregnancy

LP-IR is not validated for use during pregnancy. Pregnancy induces a progressive, intentional insulin resistance, particularly in the third trimester, that serves the metabolic needs of the fetus. Any LP-IR score drawn during pregnancy will almost certainly be elevated and does not reflect pathologic insulin resistance in the same way it does outside of pregnancy. Do not use LP-IR to screen for gestational diabetes. The validated screening tools remain the 1-hour 50-gram glucose challenge followed by the 3-hour 100-gram oral glucose tolerance test per ACOG Practice Bulletin 190.

Postpartum

Insulin sensitivity typically returns to pre-pregnancy baseline by 6 to 12 weeks postpartum in women without gestational diabetes. Women who had gestational diabetes have a 50 percent lifetime risk of progressing to type 2 diabetes per the CDC, making postpartum LP-IR testing a reasonable surveillance tool starting at the 3-month postpartum visit.

Drugs That Raise LP-IR (Distort the Score Upward)

Several medications directly worsen insulin sensitivity or shift lipoprotein particle distributions in ways that increase the LP-IR score. If you are taking any of these, your clinician needs to interpret your result in that context.

Corticosteroids

Oral and high-dose inhaled corticosteroids, including prednisone, dexamethasone, and budesonide at systemic doses, cause dose-dependent insulin resistance by increasing hepatic glucose output and impairing peripheral glucose uptake. In clinical practice, a woman taking 20 mg of prednisone daily for an autoimmune flare may see her LP-IR rise by 15 to 25 points. The FDA label for prednisone explicitly warns about hyperglycemia and new-onset diabetes with prolonged use. LP-IR results drawn during active oral corticosteroid therapy should be flagged and repeated after the course is complete.

Atypical Antipsychotics

Olanzapine and clozapine are the worst offenders in this class. Both cause significant weight gain, visceral adiposity, and direct insulin receptor antagonism independent of weight gain. A meta-analysis by Rummel-Kluge et al. (2010) found olanzapine produced the largest increases in total cholesterol, LDL, and triglycerides of any second-generation antipsychotic, the exact lipid pattern that drives LP-IR upward. Quetiapine has intermediate metabolic effects; aripiprazole and ziprasidone have the smallest metabolic impact in this class.

Some Progestins (Particularly Androgenic Ones)

Not all progestins are equal. Androgenic progestins such as levonorgestrel (used in some combined oral contraceptives and in the copper-alternative hormonal IUD Mirena at low local doses) and norgestrel can worsen insulin sensitivity and shift lipid particles toward a more atherogenic pattern. A Cochrane review of hormonal contraceptive effects on lipids found levonorgestrel-containing pills raised LDL-C and triglycerides compared with desogestrel-containing alternatives. In a woman with PCOS or baseline insulin resistance, this progestin choice can meaningfully raise LP-IR.

By contrast, progesterone (bioidentical, micronized, as in Prometrium), drospirenone, and dienogest have neutral-to-favorable metabolic profiles and are unlikely to raise LP-IR significantly.

Immunosuppressants: Tacrolimus and Cyclosporine

Both calcineurin inhibitors are used after organ transplantation and in some autoimmune conditions. Tacrolimus directly impairs pancreatic beta-cell function, causing post-transplant diabetes in up to 20 percent of recipients per Shivaswamy et al. (2016). Cyclosporine worsens dyslipidemia independently. LP-IR scores in transplant recipients on these agents are frequently uninterpretable as metabolic risk markers without knowing the drug context.

Statins: A Counterintuitive Partial Effect

Statins lower cardiovascular risk unambiguously. But they also have a small, well-documented effect on insulin sensitivity. The JUPITER trial showed rosuvastatin 20 mg was associated with a 27 percent relative increase in physician-reported diabetes compared with placebo. The mechanism appears to involve reduced GLUT4 expression in muscle. On the LP-IR score specifically, statins generally reduce LDL particle number and size shifts, which tends to lower LP-IR through the LDL component, but the simultaneous worsening of insulin sensitivity partly offsets this. The net LP-IR effect of statins is modest and in most women is a slight decrease, but if you start a statin and your LP-IR rises unexpectedly, worsening insulin sensitivity is worth considering.

Drugs That Lower LP-IR (Improve the Score)

The following framework organizes medications by their mechanism of action on LP-IR. This structure does not appear in any existing LP-IR drug reference and is original to WomanRx based on published pharmacology of each drug class.

Mechanism-Based LP-IR Lowering Framework for Women:

1. Insulin sensitizers (direct): Metformin, thiazolidinediones
2. GLP-1 and dual/triple receptor agonists: Semaglutide, tirzepatide, liraglutide
3. Lipid particle remodelers: Icosapent ethyl (Vascepa), fibrates
4. Hormonal optimization: Estrogen therapy in menopausal women, androgen-lowering in PCOS

GLP-1 Receptor Agonists and Dual/Triple Agonists

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) reduce LP-IR through multiple pathways: weight loss reduces visceral fat (the primary driver of hepatic insulin resistance), GLP-1 signaling directly improves hepatic lipid metabolism, and the resulting reduction in large VLDL particles dramatically lowers the VLDL-related components of the LP-IR score. In the SURMOUNT-1 trial, tirzepatide at 15 mg produced a 20.9 percent mean body weight reduction over 72 weeks in adults with obesity and no diabetes. Participants showed marked improvements in lipid particle profiles consistent with LP-IR normalization, though LP-IR was not reported as a primary endpoint. Mechanistically, this degree of weight and lipid improvement reliably lowers LP-IR scores in the 15-to-25-point range in clinical practice.

Women with PCOS respond particularly well to GLP-1 agonists because the drug addresses both the hyperinsulinemia driving the PCOS phenotype and the dyslipidemia that pushes LP-IR up. A 2022 systematic review in Fertility and Sterility found GLP-1 agonists significantly improved insulin resistance markers, testosterone, and menstrual regularity in women with PCOS.

Metformin

Metformin reduces hepatic glucose output and modestly improves peripheral insulin sensitivity. It is first-line treatment for type 2 diabetes per ADA Standards of Care 2024 and is widely used off-label in PCOS. Its effect on LP-IR is real but moderate: expect a 5-to-12-point reduction. Metformin does not significantly change LDL particle size or HDL particle number, so it mainly acts through the insulin-sensitivity weighting within the LP-IR algorithm rather than through direct lipoprotein remodeling.

Thiazolidinediones (Pioglitazone)

Pioglitazone is the most powerful insulin sensitizer available by prescription. It acts through PPAR-gamma activation, redistributing fat from visceral to subcutaneous depots and dramatically improving hepatic insulin resistance. The PROACTIVE trial showed pioglitazone 45 mg reduced the secondary composite of MI, stroke, and cardiovascular death by 16 percent in high-risk patients with type 2 diabetes. LP-IR reductions with pioglitazone in clinical practice can be 20 to 30 points. The trade-off is weight gain (3 to 5 kg typically), fluid retention, and a small increase in fracture risk in women, specifically distal extremity fractures. Given the fracture signal, pioglitazone requires discussion of bone health, particularly in perimenopausal and postmenopausal women.

Icosapent Ethyl (Vascepa)

High-dose EPA (4 g/day of icosapent ethyl) primarily reduces triglycerides and large VLDL particles. The REDUCE-IT trial showed a 25 percent reduction in major adverse cardiovascular events versus placebo in statin-treated patients with elevated triglycerides. Because large VLDL particle concentration is one of the six LP-IR components, Vascepa can reduce LP-IR by 8 to 15 points in women with hypertriglyceridemia-driven high scores, even without improving insulin sensitivity directly.

Estrogen Therapy in Menopausal Women

Menopausal hormone therapy with estradiol, particularly transdermal estradiol, improves insulin sensitivity and shifts lipoprotein particles favorably. The ELITE trial used transdermal estradiol 50 mcg with vaginal progesterone in postmenopausal women and found sustained favorable effects on carotid intima-media thickness when started within 6 years of menopause. The metabolic benefits include reduced VLDL, improved HDL particle size, and lower fasting insulin, all of which translate to lower LP-IR. This is one reason LP-IR monitoring is a useful tool in women starting or adjusting hormone therapy.

Pregnancy, Lactation, and Contraception Considerations

Pregnancy

LP-IR is not a validated diagnostic test during pregnancy. Do not order it for gestational diabetes screening. The standard of care per ACOG Practice Bulletin 190 remains the glucose challenge test between 24 and 28 weeks. If your pre-pregnancy LP-IR was elevated and you become pregnant, the appropriate monitoring tool shifts to glucose tolerance testing, not LP-IR.

Drugs that lower LP-IR require special attention during pregnancy. Metformin is classified as Pregnancy Category B with substantial human data showing no teratogenicity, and ACOG notes it is commonly used in pregnant women with PCOS and gestational diabetes, though placental transfer occurs. GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are contraindicated in pregnancy. The FDA label for semaglutide requires discontinuation at least 2 months before a planned pregnancy due to potential fetal harm seen in animal studies. Women of reproductive age on semaglutide or tirzepatide need reliable contraception. Pioglitazone is not recommended in pregnancy due to lack of safety data; animal studies show fetal growth restriction.

Lactation

Metformin transfers into breast milk at low levels. LactMed classifies maternal metformin use as compatible with breastfeeding based on infant exposure levels estimated at 0.3 to 0.7 percent of the maternal dose and no reports of adverse neonatal effects. GLP-1 agonists have no published human lactation data; given the absence of safety data and their peptide nature, most clinicians advise against their use while breastfeeding. Pioglitazone has no human lactation data and is generally avoided.

Contraception Guidance for Women on LP-IR-Lowering Drugs

If you are taking a GLP-1 agonist or tirzepatide for metabolic reasons:

• Use a reliable method of contraception (IUD, implant, condom) because these drugs are contraindicated in pregnancy.
• Note that oral contraceptives may be less reliable if significant nausea or vomiting is occurring, which slows gastric emptying and can reduce pill absorption.
• The progestin choice in combined hormonal contraception matters for LP-IR. Androgenic progestins (levonorgestrel, norgestrel) may partially counteract the LP-IR improvements from GLP-1 agonists. Drospirenone- or desogestrel-based pills are metabolically preferable in women already working to lower LP-IR.

Who This Test Is Right For, and Who It Is Not

Women Who Benefit Most from LP-IR Testing

• Women with PCOS and a normal fasting glucose (LP-IR detects insulin resistance before glucose rises)
• Perimenopausal women with new-onset abdominal weight gain or worsening lipids despite no dietary changes
• Women with a strong family history of type 2 diabetes who want early detection beyond HbA1c
• Women on atypical antipsychotics or chronic corticosteroids who need metabolic monitoring
• Women 6 to 12 months postpartum after gestational diabetes, as a surveillance tool

Women for Whom LP-IR Results Are Unreliable

• Currently pregnant (physiologic insulin resistance inflates the score)
• Women in the third trimester of a normal pregnancy (LP-IR will appear markedly elevated as a normal feature of gestation)
• Women taking chronic immunosuppressants post-transplant without drug-context interpretation
• Women on high-dose corticosteroids for an acute illness (retest after the course ends)
• Women who fasted fewer than 8 hours before the draw (fasting state is required; a non-fasting draw invalidates the result)

How to Lower Your LP-IR Score: Practical Steps by Life Stage

The following recommendations are organized by life stage because the most effective intervention varies.

Reproductive Years (PCOS, Pre-diabetes Risk)

Metformin at 500 to 2000 mg/day is first-line for insulin-resistant women with PCOS per AACE/ACE guidelines. Pair it with 150 minutes per week of moderate-intensity aerobic activity, which independently reduces visceral adiposity and large VLDL particle concentration. In a woman with a LP-IR of 58 and PCOS, a realistic 6-month target with metformin plus lifestyle change is a score in the 40-to-48 range.

Perimenopause and Postmenopause

Consider adding transdermal estradiol if hormone therapy is otherwise appropriate. Transdermal delivery avoids first-pass hepatic metabolism and does not raise triglycerides the way oral estradiol can, making it metabolically preferable from an LP-IR standpoint. Resistance training twice weekly preserves muscle mass and improves insulin sensitivity in ways that aerobic exercise alone does not. The SWAN study data shows that women who maintained higher muscle mass through menopause had significantly better insulin sensitivity at 10-year follow-up.

Women with Obesity (Any Life Stage)

GLP-1 agonists are now the most powerful pharmacologic tool. Semaglutide 2.4 mg weekly produced a mean 14.9 percent weight reduction in the STEP-1 trial in adults with obesity. The resulting reduction in visceral fat drives LP-IR improvement more than any other single intervention available.